Navigation Links
ThermoGenesis Corp. to Announce Third Quarter Fiscal 2011 Results On May 5, 2011
Date:4/29/2011

RANCHO CORDOVA, Calif., April 29, 2011 /PRNewswire/ -- ThermoGenesis Corp. (NASDAQ: KOOL), a leading supplier of innovative products that process and store adult stem cells, announced today it will report financial results for the fiscal third quarter ended March 31, 2011, on Thursday, May 5, 2011.

Company's Conference Call and Webcast

Management will host a conference call Thursday, May 5, 2011 at 2:00 PM Pacific (5:00 PM Eastern) to review the fiscal third quarter financial results.  

The call can be accessed by dialing 1-800-860-2442 within the U.S. or 1-412-858-4600 outside the U.S. and referencing, "ThermoGenesis." Mr. J. Melville Engle, Chairman and Chief Executive Officer and Mr. Matthew Plavan, Chief Financial Officer and Executive Vice President, Business Development will host the call to discuss the third quarter results and other corporate events, followed by a Q&A session. Participants are asked to call the assigned number approximately 5 minutes before the conference call begins.  

To listen to the audio webcast of the call during or after the event, please visit: http://www.thermogenesis.com/investors-webcasts-and-calls.aspx.

Replay

A replay of the conference call will be available two hours after the call for the following five business days by dialing 1-877-344-7529 within the U.S. or 1-412-317-0088 outside the U.S. and entering the following account number when prompted '385107'.

About ThermoGenesis Corp.

ThermoGenesis Corp. (www.thermogenesis.com) is a leading supplier of innovative products and services that process and store adult stem cells for treatment of disease and injury.

This press release contains forward-looking statements.  These statements involve risks and uncertainties that could cause actual outcomes to differ materially from those contemplated by the forward-looking statements. Several factors including timing of FDA approvals, changes in customer forecasts, our failure to meet customers' purchase order and quality requirements, supply shortages, production delays, changes in the markets for customers' products, introduction timing and acceptance of our new products scheduled for fiscal year 2011, and introduction of competitive products and other factors beyond our control could result in a materially different revenue outcome and/or in our failure to achieve the revenue levels we expect for fiscal 2011.  A more complete description of these and other risks that could cause actual events to differ from the outcomes predicted by our forward-looking statements is set forth under the caption "Risk Factors" in our annual report on Form 10-K and other reports we file with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward-looking statements.

ThermoGenesis Corp.
Web site: http://www.thermogenesis.com
Contact: Investor Relations
+1-916-858-5107, or
ir@thermogenesis.com


'/>"/>
SOURCE ThermoGenesis Corp.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ThermoGenesis Announces Registration of Res-Q in India; Commercial Sales Expected to Begin in Current Quarter
2. Major China Regenerative Medicine Company Adopts ThermoGenesis Cord Blood Stem Cell Processing And Storage Technologies
3. ThermoGenesis Reports Second Quarter 2011 Results; Increased Presence in China
4. ThermoGenesis Announces Agreement for AXP and BioArchive Cord Blood Systems With Major Chinese Stem Cell Company
5. ThermoGenesis Corp. to Announce Second Quarter Fiscal 2011 Results on February 10, 2011
6. ThermoGenesis Corp. and TotipotentSC Receive Approval for Phase Ib Clinical Trial of Res-Q™ 60 BMC for Treatment of Critical Limb Ischemia
7. ThermoGenesis Corp. Files Shelf Registration Statement on Form S-3
8. ThermoGenesis Signs Major Bone Marrow Product Distribution Agreement in China
9. ThermoGenesis Reports 35 Percent Increase in First Quarter 2011 Revenues, Adds Strategic Advisor and Inks China Distribution Deal With Nanshan Memorial Medical Institute
10. ThermoGenesis Corp. to Announce First Quarter Fiscal 2011 Results on November 4, 2010
11. ThermoGenesis Announces Platelet Rich Plasma (PRP) Res-Q Cardiovascular Licensing Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/7/2017)... 6, 2017   Provista, a proven leader ... billion in purchasing power, today announced a new resource ... The Newsroom is the online home for case ... expert bios, news releases, slideshows and events. ... wealth of resources at their fingertips, viewers can also ...
(Date:10/4/2017)... 2017 OBP Medical , a ... devices, today announced regulatory approval from ... Agência Nacional de Vigilância Sanitária (ANVISA)) to market ... retractor with integrated LED light source and smoke ... exposure of a tissue pocket or cavity during ...
(Date:10/2/2017)... Halo Labs announces the European launch of their new ... at MIBio 2017 in Cambridge, U.K on ... in biopharmaceutical samples with unprecedented speed and sensitivity while using far ... Membrane Imaging. ... particle analysis system ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The ... the most popular and least understood books in the Holy Scriptures, Revelation. The Book ... have baffled scholars for centuries. Many have tossed it off as mere rubbish, but ...
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and the loss ... author, William Nowers. Captain Nowers and his wife, Millie, have six children, ten ... the Navy. Following his career as a naval aviator and carrier pilot, he ...
(Date:10/12/2017)... ... 2017 , ... The company has developed a suite of ... authorities worldwide. From Children’s to Adults 50+, every formula has been developed by ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, Preservative ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: ... develop to enable prevention of a major side effect of chemotherapy in children. ... pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a dose ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, the ... – Miles by Moonlight to raise money for the American Heart Association Heart Walk. ... , Teams will work together to keep their treadmills moving for 5 hours. Treadmills ...
Breaking Medicine News(10 mins):